Clinical trials: B-Cell Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety…
- Conditions
- Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood
- Trial name
- NCT04204161
- Testing
- CAR-T19/CAR-T22
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
The aim of this study is to determine the maximal tolerated dose level of lenalidomide combined with fludarabine/rituximab in the therapy of patients with previously untreated CD20-positive chronic lymphocytic leukemia.
- Trial name
- NCT00738829
- Testing
- Lenalidomide, Fludarabine, Rituximab
- Where
- 7 sites in Austria
- Volunteers
- 45 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Lymphoma, Leukemia
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
Primary objective: To determine the safety of adback T- or Natural Killer (NK) cells in patients with lymphoid malignancies receiving allogeneic stem cell transplantation with Campath-IH containing conditioning regimen.
- Trial name
- NCT00536978
- Testing
- ARA-C, BCNU, Campath-1H
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
- Trial name
- NCT01029509
- Testing
- OPB 31121
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This randomized phase II trial studies how well ibrutinib works when given together with vaccine therapies in treating patients without clinical signs or indications that raise the possibility of a particular disorder or…
- Trial name
- NCT02518555
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Jennifer Woyach
Leukemia
Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00265915
- Testing
- rituximab, sargramostim
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or…
- Trial name
- NCT04477291
- Testing
- CG-806
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aptose Biosciences Inc.
AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well a dose adjusted regimen consisting of etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH) works in combination with ofatumumab or rituximab in…
- Conditions
- AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
- Trial name
- NCT02199184
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment
Chronic Lymphocytic Leukemia (CLL) is still an incurable disease. However recent advances have established correlation between the quality of the response (in particular achievement of negativity of minimal residual disease (MRD)…
- Trial name
- LLCRlowdoz (NCT01521689)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Institut Paoli-Calmettes
Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) with a safety switch will be infused back to patients with B cell malignancies, including lymphoma and leukemia.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT02456350
- Testing
- Fludarabine, Cyclophosphamide, Anti-CD19-CAR transduced T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shenzhen Second People's Hospital
Acute Leukemia, Acute Myeloid Leukemia
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further…
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma
- Trial name
- NCT03314974
- Testing
- HSCT with TBI Regimen, HSCT with Non-TBI Regimen
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Lymphocytic Leukemia
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
This phase II trial studies how well ofatumumab works as front-line therapy in treating elderly participants with chronic lymphocytic leukemia.
- Trial name
- NCT01444716
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
This is a prospective multi-center study to investigate efficacy and safety of the third generation tyrosine kinase inhibitors (TKIs) combined with azacitidine and B-cell lymphoma-2 (Bcl-2) inhibitor in patients with myeloid…
- Trial name
- NCT06390306
- Testing
- Ponatinib, Azacitidine, Venetoclax
- Where
- 15 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
B-cell Acute Lymphoblastic Leukemia
CD19-CAR-T Cells in Patients With R/R B-ALL
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of autologous or donor-derived allogeneic T cells expressing CD19 chimeric antigen receptors (referred to as "CD19-CAR-T cells")…
- Trial name
- NCT03574168
- Testing
- CD19-CAR-T Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Bioceltech Therapeutics, Ltd.
B-cell Chronic Lymphocytic Leukemia
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen
This is a Phase 2b, open-label, multicenter, global study assessing the safety and efficacy of ABT-263 in subjects with B-cell CLL who have failed at least one prior fludarabine-containing regimen.
- Trial name
- NCT00918450
- Testing
- ABT-263
- Volunteers
- 150 people
- Sponsor
- Abbott
Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults
The purpose of this study is to prospectively validate the new risk model, based on minimal residual disease (MRD) response level and oncogenetic status by comparing historical results of GRAALL-2005 with those of GRAALL-2014 in…
- Trial name
- GRAALL-2014/B (NCT02617004)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Central Nervous System Lymphoma
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
This study is a open-label, dose-escalation trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of Human CD19-CD22 Targeted T Cells by intravenous and intrathecal administration, and to…
- Trial name
- NCT05651178
- Testing
- Human CD19-CD22 Targeted T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Lymphoma
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Trial name
- NCT00005985
- Testing
- filgrastim, carmustine, cyclophosphamide
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body.
- Conditions
- Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor Malignancies
- Trial name
- NCT07749976
- Testing
- VTRU200
- Volunteers
- 108 people
- Sponsor
- Vitruviae
Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
The objective of this Phase I clinical trial is to evaluate the safety, toxicity profile, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of autologous CAR-T anti-CD19 cell therapy (CAR-T ANTI-CD19 COL01) in…
- Conditions
- Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL)
- Trial name
- COLIBRÍ (NCT07883941)
- Testing
- CAR-T anti-CD19 COL01
- Volunteers
- 12 people
- Sponsor
- GUSTAVO SALGUERO